Reading #NGL Fine Chem’s latest concall, it is very apparent that while the management is very good, the competitive structure of the industry does not allow them to have any sort of pricing power.
Some snippets from the Q2 concall looked at through the lens of Porter’s 5 forces that tell us that the company will do good in the next few quarters as commodity prices stabilize. But they will be back here again the next time commodity prices increase.
Bargaining power of customers: The company can pass on cost increases with a lag. But when commodity prices come down, the decrease in price for their products is immediate.
Threat of substitutes: The management has said that when prices for their products increase, the end customer will just shift to substitute products or just choose not treat the livestock
Rivalry among competitors: They operate in a B2B model with no branding or product differentiation. So it is very easy for competitors to undercut your prices
Threat of new entrants: The company operates in lesser regulated markets. This market is usually made up of many small and unorganized players as the costs to set up the manufacturing facilities is a fraction of what it is for the regulated markets.
This low cost makes it very easy for new players to enter, reducing overall margins.
Bargaining power of suppliers: The company is backward integrated and mostly only purchases basic commodities. So no particular supplier has much power over them.
However, they are not big enough either to be able to negotiate lower prices with their suppliers.
Therefore, the business model does not allow them to have any meaningful competitive advantage.
1. Introduction
-Deepak Nitrite is one of the leading chemical intermediates manufacturers of basic as well as specialty chemicals.
-The company initially started off with small-scale manufacturing of sodium nitrite and sodium nitrate and gradually widened its product portfolio
to offer more than 100 products to more than 1000 customers across 30 countries.
-It has its presence in Basic Intermediates, Fine & Specialty Chemicals, Performance Products and Phenolics.
-Deepak Nitrite Ltd (DNL) has been a front runner in tapping import substitution
Key highlights from PI Industries Q2 FY23 concall 🧪🧪
Like and Retweet for maximum reach!!
In CSM exports, the company has an order book of around $1.8 billion. The company plans to get revenues for 3 to 4 years based on this order book
The order book of the company increased by $400 million to $1.8 billion. However, the major contribution in this order book will be from the agrochemical space while the non-agrochemical space won’t have a very significant share as most of them are still at R&D scale or pilot
The outlook for #Hester Biosciences’ does not seem very strong for the next year. They are facing major issues in multiple segments. Some takeaways from their Q2 FY23 concalls below⚠️⚠️
Their poultry business, which is their largest vertical, is not doing well as cost of raw materials has increased and demand for the end product has been decreasing. Poultry farmers are trying to reduce input costs which means lower demand for Hester’s products.
The company’s product mix is shifting from mainly vaccines toward animal health products which are generally lower in margin than vaccines. This issue is also made worse by the increase in raw material prices for their health products which is further reducing margins.
Gufic is an R&D focused pharma company that is involved in contract manufacturing, branded generics, herbal formulations and new drug delivery systems.
The company entered into the contract manufacturing business in 2007 and today it manufactures
lyophilized injectables for most of the large pharma companies in India.
Company then entered the branded generics business with the launch of several products in the critical care space.
#Indoco Remedies’ management seems to be very optimistic about strong expansion in margins. They have an export order book of ₹150 with export margins expected to increase by 400-500 bps over the next 3 quarters.
They will achieve EBITDA margins over 20% in this financial year and have said that they are confident of taking margins to over 25% over the next 3 years.
Management has said that there is huge scope for operating leverage to play out at the Baddi facility. They expect to reach 70% capacity utilization by December 2023